Breaking News

Financial Reports: Merck & Co.

By Gil Roth | July 30, 2013

Singulair generics, strong dollar drag down revenues

Merck 2Q13

2Q Revenues: $11.0 billion (-11%)

2Q Earnings: $906 million (-50%)

YTD Revenues: $21.7 billion (-10%)

YTD Earnings: $2.5 billion (-29%)

Comments: An 80% drop in Singulair sales led to a $1.1 billion shortfall in revenues for Merck in 2Q13, wiping out scant gains for top products Januvia (+1% to $1.1 billion), Zetia (+3% to $650 million), Remicade (+2% to $527 million) and Janumet (+16% to $474 million). A stronger dollar also hurt Januvia revenues, which would have posted 7% growth at constant exchange rates. For YTD, Januvia sales are down 1% to $2.0 billion, while Janumet sales are up 10% to $802 million. Consumer Care revenues fell 11% to $490 million in the quarter, after the termination of some distribution arrangements in China and a reversal of sales previously made to its distributors.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments